BRAIN Biotech AG

Equities

BNN

DE0005203947

Environmental Services & Equipment

Market Closed - Xetra 11:36:01 2024-04-26 am EDT 5-day change 1st Jan Change
2.88 EUR +4.73% Intraday chart for BRAIN Biotech AG +0.70% -21.31%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Brain Biotech Plans Merger by Absorption of AnalytiCon Discovery MT
BRAIN Biotech AG and AMSilk GmbH Announce the Successful Completion of the First Phase of A Development Collaboration CI
BRAIN Biotech AG Reports Earnings Results for the First Quarter Ended December 31, 2023 CI
BRAIN Biotech AG Reports Earnings Results for the Full Year Ended September 30, 2023 CI
BRAIN Biotech AG Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023 CI
BRAIN Biotech AG Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023 CI
Transcript : BRAIN Biotech AG, Q2 2023 Earnings Call, May 25, 2023
BRAIN Biotech to Look Acquisitions CI
BRAIN Biotech AG acquired remaining 17.8% stake in Biocatalysts Limited for ?9.6 million. CI
SolasCure Limited announced that it has received £10.9 million in funding from Seneca Partners Limited, BRAIN Biotech AG, Eva Pharma Consultants Ltd, Wealth Club Limited and another investor CI
BRAIN Biotech AG announced that it expects to receive ?5 million in funding from MP Beteiligungs-Gmbh CI
BRAIN Biotech AG Reports Earnings Results for the First Quarter Ended December 31, 2022 CI
BRAIN Biotech Ends Contract with Roquette Frères on Natural Sweetener Joint Development MT
BRAIN Biotech Unit to Focus on Developing New Therapies Via Genome-editing Technology MT
BRAIN Biotech AG Announces Executive Changes CI
BRAIN Biotech AG Reports Earnings Results for the Full Year Ended September 30, 2022 CI
La Cultura Verde Ltd. acquired LA Schmitt from BRAIN Biotech AG. CI
BRAIN Biotech AG Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2022 CI
BRAIN Biotech AG Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2022 CI
Brain Biotech Ag Announces Resignation of Bernhard Hauer from Supervisory Board, as of May 31, 2022 CI
Brain Biotech AG Announces Successful Genome Editing Activity in Mammalian Cells with BRAIN-Metagenome-Cas, BRAIN-Engineered-Cas CI
BRAIN Biotech AG Reports Earnings Results for the First Quarter Ended December 31, 2021 CI
BRAIN Biotech AG and Formo Bio GmbH Launch A Strategic Collaboration to Further Advance the Production of Animal-Free Milk Proteins CI
BRAIN Biotech AG Reports Earnings Results for the Full Year Ended September 30, 2021 CI
BRAIN Biotech AG Announces That It Is Extending Its Proprietary Genome-Editing Toolbox with the Addition of Brain-Metagenome-Cas 01 Nuclease CI
Chart BRAIN Biotech AG
More charts
BRAIN Biotech AG, formerly known as BRAIN Biotechnology Research and Information Network AG is a Germany-based industrial biotechnology company develops and brings to market biological ingredients for Nutrition & Health, SkinCare and Industrial BioSolutions. Research & Development activities focus on bioactive natural compounds, tailored enzymes and high-performance microorganisms.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.88 EUR
Average target price
10.98 EUR
Spread / Average Target
+281.08%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. BNN Stock
  4. News BRAIN Biotech AG
  5. BRAIN Biotech Ends Contract with Roquette Frères on Natural Sweetener Joint Development